Microbiome-Based Therapies in Ulcerative Colitis: Mechanisms, Clinical Evidence, and a Precision-Medicine Framework

Area of Science:

• Gastroenterology and immunology
• Microbiome research
• Therapeutic development

Background:

• Ulcerative colitis (UC) is a chronic condition with limited treatment options, leading to significant unmet clinical needs.
• The gut microbiome plays a crucial role in UC pathogenesis, affecting gut barrier, immunity, and metabolism.
• Current therapies often have limited efficacy or cause adverse effects in many UC patients.

Purpose of the Study:

• To review and synthesize mechanistic and clinical data on microbiome-based therapies for UC.
• To compare the strategies and efficacy of fecal microbiota transplantation (FMT) and defined microbial consortia.
• To propose a precision-medicine framework for selecting microbiome therapies in UC.

Main Methods:

• Literature review of randomized controlled trials and early-phase studies on microbiome interventions for UC.
• Analysis of mechanistic insights for both broad (FMT) and defined microbial consortia.
• Synthesis of clinical evidence regarding therapeutic outcomes and patient responses.

Main Results:

• Fecal microbiota transplantation (FMT) acts as a broad ecological intervention, restoring microbial diversity.
• Defined microbial consortia offer targeted modulation of specific metabolic and immune pathways.
• Evidence suggests consortia with broader mechanistic coverage may lead to more consistent therapeutic activity in UC.

Conclusions:

• Microbiome-based therapies, including FMT and defined consortia, are emerging as promising treatments for UC.
• A precision-medicine approach, aligning therapy mechanisms with patient profiles, is crucial for optimizing UC treatment.
• Future directions include biomarker-guided patient selection, hybrid consortia, and adaptive trial designs to advance UC microbiome therapy.